Summary of ongoing reslizumab studies in patients with eosinophilic asthma. | Download Table
Reslizumab Overview - Creative Biolabs
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
CINQAERO (reslizumab) de Teva ya está disponible en España para el asma grave no controlada | IM Farmacias
Brand name: Auvi-Q
CINQAIR® (reslizumab) Injection – About Asthma Control
Medication Detail
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Reslizumab | New Drug Approvals
Reslizumab | Teva UK
Teva's Asthma Segment: What Could Boost Its Revenues in 2016?
Teva Announces Biologics License Application FDA Acceptance of Reslizumab For Asthma
Teva filled Biologics License Application for reslizumab Archives • NCK Pharma
Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
Dosing and Administration
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval
TA479 Review decision paper
Reslizumab
Cinqair (Reslizumab) 100mg/10mL Injection – Apothera
NICE changes mind and backs new drug for severe asthma | Nursing Times
Improving Eosinphilic Asthma with Reslizumab Add-On Treatment
